C5 Complement Inhibitors Market Report 2026

C5 Complement Inhibitors Market Overview

• C5 Complement Inhibitors market size has reached to $7.84 billion in 2025 • Expected to grow to $14.93 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Rising Prevalence Of Chronic Diseases Driving The Demand For The Market Due To Increasing Cases Of Immune-Mediated Disorders • Market Trend: Advancements In Subcutaneous Injections Enhancing Treatment Convenience And Effectiveness • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under C5 Complement Inhibitors Market?

C5 complement inhibitors are a class of targeted immunomodulatory biologic agents that specifically block the cleavage of complement component 5 (C5) into its active fragments C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and mitigating downstream inflammatory and cytolytic processes associated with overactivation of the complement system. These inhibitors are used in the treatment of complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and certain forms of generalized myasthenia gravis, where excessive complement activity contributes to disease pathology. The main products in C5 complement inhibitors are long acting C5 inhibitors and short acting C5 inhibitors. Long-acting C5 complement inhibitors are therapeutic agents designed to provide prolonged suppression of complement component 5 (C5) activity, reducing the frequency of administration while maintaining effective control over immune-mediated conditions. The drugs included in these are eculizumab, ravulizumab, and others, which are given by routes of administration including intravenous, subcutaneous, and oral, distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies for the applications in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and others.

What Is The C5 Complement Inhibitors Market Growth Forecast?

The c5 complement inhibitors market size is expected to see rapid growth in the next few years. It will grow to $14.93 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune and rare diseases, expansion of personalized medicine approaches, pipeline growth of next-generation inhibitors, rising biologics manufacturing capacity, supportive regulatory pathways for orphan drugs. Major trends in the forecast period include growing adoption of targeted immunotherapies, rising use in rare complement-mediated disorders, increasing preference for long-acting formulations, expansion of combination treatment approaches, growing focus on early diagnosis and intervention.

Global C5 Complement Inhibitors Market Segmentation

1) By Product: Long Acting C5 Inhibitors, Short Acting C5 Inhibitors 2) By Drug: Eculizumab, Ravulizumab, Other Drugs 3) By Route Of Administration: Intravenous, Subcutaneous 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 5) By Application: Paroxysmal Noctural Hemoglobuinuria, Atyptical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optics Spectrum Disorder, Other Applications Subsegments: 1) By Long Acting C5 Inhibitors: Crovalimab, Pozelimab, Tesidolumab, Other Long-Acting C5 Inhibitors 2) By Short Acting C5 Inhibitors: Zilucoplan, Cemdisiran, Nomacopan, Other Short-Acting C5 Inhibitors

What Is The Driver Of The C5 Complement Inhibitors Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the C5 complement inhibitors market going forward. Chronic diseases are long-term medical conditions that progress slowly and persist over time, often requiring continuous medical attention and management to prevent complications. The increasing prevalence of chronic diseases is largely driven by lifestyle changes such as poor diet, physical inactivity, smoking, and stress, which contribute to long-term health deterioration. C5 complement inhibitors help chronic disease patients by blocking the overactivation of the complement system, thereby reducing inflammation, preventing tissue damage, and improving disease outcomes in conditions such as PNH, aHUS, and other complement-mediated disorders. For instance, in April 2025, according to a International Diabetes Federation, a Belgium-based non-profit organization, in 2024, more than 9.5 million people were living with type 1 diabetes, including 1.9 million children and adolescents under 20. By 2050, the global diabetes population is expected to climb to 853 million. Therefore, the increasing prevalence of chronic diseases is driving the growth of the C5 complement inhibitors industry.

Key Players In The Global C5 Complement Inhibitors Market

Major companies operating in the c5 complement inhibitors market are AstraZeneca plc, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Akari Therapeutics Plc, Regeneron Pharmaceuticals Inc., UCB Pharma SA, Astellas Pharma Inc., InflaRx NV, Alexion Pharmaceuticals Inc., Ra Pharmaceuticals Inc., ChemoCentryx Inc., Annexon Biosciences Inc., Iveric Bio Inc., Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Inc.

Global C5 Complement Inhibitors Market Trends and Insights

Major companies operating in the C5 complement inhibitors market are focusing on developing novel therapies, such as self-administered C5 inhibitors, to expand treatment options for generalized myasthenia gravis. A self-administered C5 inhibitor is a targeted therapeutic agent that blocks the complement C5 protein to reduce inflammation and immune-mediated damage, designed for patient-administered use to treat conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. For instance, in October 2023, Union Chimique Belge (UCB) SA, a Belgium-based biopharmaceutical company, announced Zilbrysq (zilucoplan) for treating adults with generalized myasthenia gravis (gMG) approved by the Food and Drug Administration (FDA), a US-based government regulatory agency. This approval applies specifically to patients who are anti-acetylcholine receptor (AChR) antibody-positive, a common form of the disease. Zilbrysq is a self-administered, once-daily, subcutaneous C5 complement inhibitor, offering a new treatment option for gMG patients. The approval strengthens UCB’s neurology portfolio, expanding treatment choices for individuals with autoimmune neuromuscular disorders.

What Are Latest Mergers And Acquisitions In The C5 Complement Inhibitors Market?

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio Inc., for $5.9 billion. With this acquisition, Astellas Pharma aims to strengthen its ophthalmology pipeline and expand its presence in the retinal disease market by gaining access to Iveric Bio’s lead asset, Zimura, a promising treatment for geographic atrophy secondary to age-related macular degeneration. Iveric Bio Inc. is a US-based biopharmaceutical company developing a complement C5 inhibitor.

Regional Insights

North America was the largest region in the C5 complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the C5 Complement Inhibitors Market?

The C5 complement inhibitors market consists of sales of zilucoplan, cemdisiran, tesidolumab, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the C5 Complement Inhibitors Market Report 2026?

The c5 complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the c5 complement inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.